Uscom Limited · ASX:UCM
Uscom — Corporate Update (May 2020)
25 slides from Uscom's corporate update, May 1, 2020
Slide 1: Q4 Briefing 2020
Q4 Briefing 2020 ASX: UCM Prof. Rob Phillips PhD(Med), MPhil(Med), FASE, DMU(Cardiol) Chairman, CEO, Chief Scientist, Uscom Limited, Sydney, Australia May 1ST 2020 Critical Care Research Group, School of Medicine, The University of Queensland, Brisbane, Australia
Slide 2: CEO statement on Uscom focus and growth
“Uscom has a dedicated focus on the development and marketing of innovative non- invasive cardiovascular and pulmonary medical devices Current record revenue growth is from the USCOM 1A, and we have a constellation of new products in development and approaching regulatory approval worldwide to gener
Slide 3: 2020: Q3 Results
2020: Q3 RESULTS 3 ↑ 63% 2.41 2.5 ↑ 135% ASX:UCM 2 2 Profit up $0.96M 1.48 1.5 ↑ $0.96M ↑ $1.39M Cash flow up $1.39M Cash receipts up 135% $M 1 0.87 0.85 0.74 Cash on hand up 63% 0.5 Debt free 0 Profit Cash Flow Cash Receipts Cash on Hand -0.22 -0.5 -0.52 -1 Q3 FY19 Q3 FY20
Slide 4: Operations
OPERATIONS 1. Q3 - Profitable, cash flow positive, record cash receipts, cash on hand, debt free 2. Uscom China continues growth with strong Q4 orders 3. Europe and US COVID -19 sales activity increasing 4. Lung recovery monitoring for all COVID patients 5. New products for market in second half Usc
Slide 5: The Uscom Mission
THE USCOM MISSION Ambitious and growth driven Who We Are Our Vision Our Drive Uscom are the experts in circulation Uscom areinnovative, delivering the experts in circulation practice changing To improve clinical care in AA commercial commercial ambition ambition to become to become a leaderain disea
Slide 6: Product Suites
PRODUCT SUITES Uscom cardiovascular and pulmonary devices address diseases which account for >75% of global mortality SpiroSonic USCOM 1A BP+ COVID-19, ASTHMA, COPD, OLD SEPSIS (COVID-19), HEART HYPERTENSION, VASCULAR DIS. Uscom digital ultrasonic spirometers FAILURE, FLUID Central and brachial bloo
Slide 7: Growing Global
GROWING GLOBAL • London • Beijing • Budapest • LA Operations Sydney Beijing Budapest • Singapore Offices Singapore Auckland • Sydney London • Auckland LA Multiple products, currencies and markets RAP©
Slide 8: People
PEOPLE Rob Phillips Nick Schicht Teresa Guo Lucy Lu Lebron Wei Denise Pater Rik Denicke George Ferenczi Nancy Wang Scarlett Zhang Curt Grosse Daniel Kenig Richard Scott Zsofia Kertesz Crystal Lin George Tang Susanna Sun Andrea Marosan 37 employees 4 continents Antonio Ferrario Szabo Gergo Catherine
Slide 9: COVID-19
COVID-19 Viral lung infection ultimately may infect ~30M patients worldwide and kill ~0.5M This has prompted a transformational response from health systems worldwide with a commitment to massive spending over the next two years Precision, non-invasive medical devices will be an important part of th
Slide 10: COVID-19 and USCOM 1A
COVID-19 and USCOM 1A 1. RESPIRATORY SUPPORT – VENTILATORS SEVERE COVID- Simple and common 19 TREATMENT 2. CARDIOVASCULAR (in the absence of a vaccine) SUPPORT – USCOM 1A Less common but more critical The / Measure / of / Life USCOM 1A supports management of heart and vessels
Slide 11: COVID-19 and USCOM 1A
COVID-19 and USCOM 1A COVID-19 patients on ventilators ~90% mortality Ventilators not the solution COVID-19 patients with cardiovascular damage have 10x mortality – Heart and vessels critical “VENTILATORS ARE EVERYWHERE, BUT USCOM IS NOW BEING RECOGNISED IN INSTITUTIONS OF EXCELLENCE” Uscom – The Me
Slide 12: USCOM 1A China Government Recommendations
COVID-19 and USCOM 1A USCOM 1A China Government Recommendations Recommended by Chinese National Health and Medical Commission of the People’s Republic of China for Treatment of Severe Coronavirus in Adults and Children The China National Health and Medical Commission of the People’s Republic of Chin
Slide 13: USCOM 1A SCCM Pediatric Sepsis Guidelines
SEPSIS IN CHILDREN (COVID-19) USCOM 1A SCCM Pediatric Sepsis Guidelines International Guidelines from US, UK, Europe, Canada, S America, India, Australia 51 Authors, 25% of authors are USCOM users or advocates Weiss SL, Alhazzani W, Flori HM et al. Surviving Sepsis Campaign International Guidelines
Slide 14: COVID-19 The Future
COVID-19 THE FUTURE COVID Pulmonary Fibrosis ~10M COVID-19 infections worldwide Digital ultrasonic spirometry most accurate method of monitoring changes Recovery complicated by pulmonary fibrosis and reduced lung function Clinic, eHealth and home care The long term effects of COVID-19 on lung Market
Slide 15: COVID-19 Recovery - New Product
COVID-19 RECOVERY - NEW PRODUCT New Product - SpiroSonicAIR for the acute and chronic recovery phases of COVID-19 with pulmonary fibrosis, asthma and COPD World leading spirometers 1. Digital multi-path ultrasonic technology 2. High sensitivity (2.5%), durable, simple disinfection 3. Wireless connec
Slide 16: New Product – Ventilator Test
NEW PRODUCT – VENTILATOR TEST VentiTest is a multi-path ultrasonic ventilator test device with PC based display and analytics designed for pressure and flow testing and calibration of ventilator outputs. Uscom is increasing manufacture and marketing of VentiTest Hospital Departments need 1 VentiTest
Slide 17: Uscom for All Phases of COVID-19
USCOM FOR ALL PHASES OF COVID-19 “Uscom for the acute, critical and recovery phases of COVID-19” COVID-19 is a respiratory virus which is often impairs lung and can be complicated by pneumonia, sepsis and pulmonary fibrosis. 1. Pulmonary consolidation – SpiroSonicAIR 2. Sepsis and cardiovascular fai
Slide 18: Innovation: Uscom Digital Spirometry
INNOVATION Uscom technology Uscom Digital Spirometry provides the highest quality personal spirometers allowing U l t r a s o n i c F l o w Te c h n o l o g y home lung function testing at research standards. “FOR MEDICAL TECHNOLOGY COMPANIES INNOVATION DETERMINES FUTURE REVENUE USCOM CONTINUES TO D
Slide 19: A&D Partnership for BP+
A&D PARTNERSHIP FOR BP+ Hypertension is common and dangerous 40% of all people over 25yrs have hypertension Hypertension complicated by Heart Attack, Stroke, and kidney failure Hypertension is responsible for 7.5M US deaths Management is widely ineffective $130B spent on US hypertension yet only 20%
Slide 20: Strategy
STRATEGY 1. Focus on China sales and distribution expansion 2. Grow Europe and US sales activities around COVID-19 3. New products for global markets – BP+, SpiroSonicAIR and VENTITEST 4. Develop eHealth features for COVID-19 recovery monitoring 5. Grow global manufacturing capabilities to meet dema
Slide 21: UCM - Tightly Held
UCM - TIGHTLY HELD Shareholding Quality growth stock NED Invested management CEO Undergoing revaluation Ex CEO Investor 1 Free Investor 2a Float Investor 2b 31% Investor 3 ~150M FPO UCM shares on issue Distributor ~35±10c (Current price 24c) Investor 4 China Director ~$35M Cap Value Investor 5 Top 2
Slide 22: Summary
SUMMARY 1. Profitable, cash flow positive, record cash receipts, cash on hand and debt free 2. Continuing strong growth forecasts for Uscom China 3. Europe and US distribution showing sales pipeline growth (COVID-19) 4. COVID-19 recovery monitoring likely to impact device demand in US 5. Sustained o
Slide 23: Conclusion
CONCLUSION “Uscom has an established growth history, with rapidly transforming fundamentals and a clear strategy focused on more products and more distribution Uscom is part of the emergency global response to the Coronavirus pandemic, and is now developing strategies to manage COVID-19 recovery pat
Slide 24: Q4 Briefing 2020
Q4 Briefing 2020 ASX: UCM Prof. Rob Phillips PhD(Med), MPhil(Med), FASE, DMU(Cardiol) Chairman, CEO, Chief Scientist, Uscom Limited, Sydney, Australia May 1ST 2020 Critical Care Research Group, School of Medicine, The University of Queensland, Brisbane, Australia
Slide 25: Uscom - improving the quality of life for us all
UCM – Investor Presentation April 2020 Uscom - improving the quality of life for us all